Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study

BACKGROUND: Lecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain fibrillar amyloid reduction and slowing of clinical decline in early AD. The objective of this analysis is to report results from study 201 blinded per...

Descripción completa

Detalles Bibliográficos
Autores principales: McDade, Eric, Cummings, Jeffrey L., Dhadda, Shobha, Swanson, Chad J., Reyderman, Larisa, Kanekiyo, Michio, Koyama, Akihiko, Irizarry, Michael, Kramer, Lynn D., Bateman, Randall J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768996/
https://www.ncbi.nlm.nih.gov/pubmed/36544184
http://dx.doi.org/10.1186/s13195-022-01124-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768996/
https://www.ncbi.nlm.nih.gov/pubmed/36544184
http://dx.doi.org/10.1186/s13195-022-01124-2

Ejemplares similares